Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

• Status: Completed
• Trial end date: 2004-08-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, pork; isophane insulin, pork drug combination 30:70

Criteria

Inclusion Criteria:

• Diabetes mellitus (type 1 or type 2)

• Patient not presently using Mixtard® 30 NovoLet®